Bill · S. 3064· Senate(119-S-3064)
Relief of Chronic Pain Act of 2025
- Introduced
- 10/28/2025
- Last activity
- 10/28/2025 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Steve Daines
- Cosponsors
- - 3 - 2
- Introduced
- In Committee
What this bill would do
The Relief of Chronic Pain Act of 2025 amends the Social Security Act to improve access to certain non-opioid pain management drugs under Medicare Part D. Starting January 1, 2026, the bill ensures that qualifying non-opioid drugs for chronic pain conditions are not subject to a deductible. These specific medications must also be placed on the lowest cost-sharing tier for plans. Additionally, the legislation prohibits prescription drug plans from imposing step therapy requirements involving opioids or prior authorization for these qualifying drugs. The bill explicitly defines qualifying chronic pain conditions as lasting longer than three months, such as fibromyalgia, endometriosis, and neuropathic pain.
Yes· 3 of 9
Would people over 65 be better off under this?+8
The legislation directly benefits Medicare beneficiaries by lowering out-of-pocket costs and removing access barriers for necessary chronic pain medications.
Would retired people be better off under this?+8
Retirees on Medicare benefit significantly from the removal of deductibles and lower cost-sharing for qualifying non-opioid pain drugs.
Does this lower the price of prescription medicines?+8
The bill reduces out-of-pocket costs for qualifying non-opioid chronic pain drugs under Medicare Part D by removing deductibles and placing them on the lowest cost-sharing tier.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 2(a) removes the Medicare Part D deductible for qualifying non-opioid chronic pain management drugs and places them on the lowest cost-sharing tier starting January 1, 2026. This could benefit individuals by making these specific non-opioid treatments more affordable.
-
Section 2(b) applies these same cost-sharing protections and deductible exemptions to low-income individuals under Medicare Part D. This ensures that lower-income patients also receive financial relief on qualifying non-opioid pain medications.
-
Section 3 prohibits prescription drug plans from requiring step therapy where an individual must use an opioid before receiving the qualifying non-opioid drug. This provision also bans plans from requiring prior authorization for these medications, which could help people get their prescribed non-opioid treatments faster without administrative delays.
Potential Negative Impacts for People
- Based on the provided text, there are no specific sections or provisions identified that outline negative consequences or burdens for individuals or groups of people in the United States.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Retirees+8Good For Seniors+8Good For Low Income Households+7Good For People With Disabilities+6Good For Women+6Good For Middle Class Households+5
- Healthcare
- Reduces Prescription Drug Costs+8Improves Healthcare Access+7Improves Opioid Crisis Response+6
- 6/24/2026
- 1 Cosponsor added.
- 5/18/2026
- 1 Cosponsor added.
- 5/12/2026
- 1 Cosponsor added.
- 5/11/2026
- 1 Cosponsor added.
- 10/28/2025
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
Maria CantwellDemocrat · Washington
Timothy KaineDemocrat · Virginia
Roger MarshallRepublican · Kansas
Tim SheehyRepublican · Montana
Thomas TillisRepublican · North Carolina